A detailed history of Polar Capital Holdings PLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Polar Capital Holdings PLC holds 206,632 shares of LEGN stock, worth $8.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
206,632
Previous 156,075 32.39%
Holding current value
$8.3 Million
Previous $8.75 Million 4.54%
% of portfolio
0.06%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $2 Million - $2.89 Million
50,557 Added 32.39%
206,632 $9.15 Million
Q1 2024

May 15, 2024

SELL
$55.06 - $69.99 $66.9 Million - $85 Million
-1,214,401 Reduced 88.61%
156,075 $8.75 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $28.7 Million - $35 Million
-501,642 Reduced 26.8%
1,370,476 $82.5 Million
Q2 2023

Dec 13, 2023

SELL
$46.28 - $75.01 $4.79 Million - $7.76 Million
-103,513 Reduced 5.24%
1,872,118 $129 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $4.79 Million - $7.76 Million
-103,513 Reduced 5.24%
1,872,118 $129 Million
Q1 2023

Dec 13, 2023

BUY
$43.42 - $57.37 $4.49 Million - $5.94 Million
103,513 Added 5.53%
1,975,631 $95.3 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $39.7 Million - $52.5 Million
914,764 Added 86.23%
1,975,631 $95.3 Million
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $265,780 - $379,901
6,850 Added 0.65%
1,060,867 $53 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $18.3 Million - $27.4 Million
479,930 Added 83.6%
1,054,017 $43 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $6.68 Million - $11 Million
199,217 Added 53.14%
574,087 $31.6 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $11.6 Million - $18.1 Million
374,870 New
374,870 $13.6 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.